Kidney Transplant Rejection Clinical Trial
— EWKTPOfficial title:
Effectiveness of a Psychological Intervention Focused on Expressive Writing in Patients Undergoing to Kidney Transplant
NCT number | NCT04143178 |
Other study ID # | 08/2019 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | June 30, 2019 |
Verified date | November 2019 |
Source | University of Roma La Sapienza |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Kidney transplantation is a replacement treatment for chronic renal failure that improves
quality of life. However, it can be experienced as traumatic in relation to the changes it
entails in terms of lifestyle, redefinition of one's body and social and family role. A
negative personal experience could affect adherence to the treatment, a protective factor in
reducing the risk of organ rejection and mortality. Some studies have shown the effectiveness
of expressive writing in reducing the symptoms and management of the disease in patients
undergoing surgery or suffering from cancer. It is hypothesized that this technique allows
the processing of traumatic events linked to the disease, favoring an improvement in the
expression and emotional regulation skills.
The aim of the present study was to evaluate the effectiveness of a psychological
intervention focused on expressive writing on the post-operative course in patients underwent
to kidney transplantation. Thirty-five patients were recruited at the kidney transplant
center of the Policlinico Umberto I, Rome. The sample was divided into 2 groups: the
psychological intervention focused on expressive writing group and the control group which
carried out a neutral writing task. Each patient filled some self-report questionnaires and
carried out blood analysis, before the operation, the day of discharge and at 3 month
follow-up. The psychological intervention group was expected to have a greater improvement in
the emotional skills, adherence and renal function, and a lower level of healthcare costs
compared to the control group.
Status | Completed |
Enrollment | 35 |
Est. completion date | June 30, 2019 |
Est. primary completion date | February 14, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Adult patients (>18 years) of Italian nationality with sufficient level of education in order to understand the questionnaires and to carry out the writing task required by the protocol. Exclusion Criteria: - Patients with major psychopathology and/or cognitive impairment |
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Policlinico Umberto I Sapienza University of Rome | Roma |
Lead Sponsor | Collaborator |
---|---|
University of Roma La Sapienza | Azienda Policlinico Umberto I |
Italy,
Buda B. Stephen J. Lepore & Joshua M. Smyth (Eds.) (2002). The Writing Cure: How Expressive Writing Promotes Health and Emotional Well-Being. By Béla Buda. Crisis. 2002 May;23(3):139. — View Citation
Calia R, Lai C, Aceto P, Luciani M, Camardese G, Lai S, Amato G, Pietroni V, Salerno MP, Pedroso JA, Romagnoli J, Citterio F. Attachment style predict compliance, quality of life and renal function in adult patients after kidney transplant: preliminary results. Ren Fail. 2015 May;37(4):678-80. doi: 10.3109/0886022X.2015.1010989. Epub 2015 Feb 17. — View Citation
Calia R, Lai C, Aceto P, Luciani M, Camardese G, Lai S, Fantozzi C, Pietroni V, Salerno MP, Spagnoletti G, Pedroso JA, Romagnoli J, Citterio F. Emotional self-efficacy and alexithymia may affect compliance, renal function and quality of life in kidney transplant recipients: results from a preliminary cross-sectional study. Physiol Behav. 2015 Apr 1;142:152-4. doi: 10.1016/j.physbeh.2015.02.018. Epub 2015 Feb 11. — View Citation
Calia R, Lai C, Aceto P, Luciani M, Romagnoli J, Lai S, Gargiulo A, Citterio F. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. Transplant Proc. 2011 May;43(4):1020-3. doi: 10.1016/j.transproceed.2011.03.048. — View Citation
De Pasquale C, Veroux M, Indelicato L, Sinagra N, Giaquinta A, Fornaro M, Veroux P, Pistorio ML. Psychopathological aspects of kidney transplantation: Efficacy of a multidisciplinary team. World J Transplant. 2014 Dec 24;4(4):267-75. doi: 10.5500/wjt.v4.i4.267. Review. — View Citation
Fallon M, Gould D, Wainwright SP. Stress and quality of life in the renal transplant patient: a preliminary investigation. J Adv Nurs. 1997 Mar;25(3):562-70. — View Citation
Gallo I, Garrino L, Di Monte V. [The use of expressive writing in the course of care for cancer patients to reduce emotional distress: analysis of the literature]. Prof Inferm. 2015 Jan-Mar;68(1):29-36. doi: 10.7429/pi.2015.681029. Review. Italian. — View Citation
Gremigni P, Bacchi F, Turrini C, Cappelli G, Albertazzi A, Bitti PE. Psychological factors associated with medication adherence following renal transplantation. Clin Transplant. 2007 Nov-Dec;21(6):710-5. — View Citation
Klein K, Boals A. Expressive writing can increase working memory capacity. J Exp Psychol Gen. 2001 Sep;130(3):520-33. — View Citation
Lai C, Aceto P, Luciani M, Fazzari E, Cesari V, Luciano S, Fortini A, Berloco D, Canulla F, Bruzzese V, Lai S. Emotional management and biological markers of dietetic regimen in chronic kidney disease patients. Ren Fail. 2017 Nov;39(1):173-178. doi: 10.1080/0886022X.2016.1256312. Epub 2016 Nov 15. — View Citation
McGuire KM, Greenberg MA, Gevirtz R. Autonomic effects of expressive writing in individuals with elevated blood pressure. J Health Psychol. 2005 Mar;10(2):197-209. — View Citation
Norman SA, Lumley MA, Dooley JA, Diamond MP. For whom does it work? Moderators of the effects of written emotional disclosure in a randomized trial among women with chronic pelvic pain. Psychosom Med. 2004 Mar-Apr;66(2):174-83. — View Citation
Pabst S, Bertram A, Zimmermann T, Schiffer M, de Zwaan M. Physician reported adherence to immunosuppressants in renal transplant patients: Prevalence, agreement, and correlates. J Psychosom Res. 2015 Nov;79(5):364-71. doi: 10.1016/j.jpsychores.2015.09.001. Epub 2015 Sep 18. — View Citation
Pennebaker JW, Beall SK. Confronting a traumatic event: toward an understanding of inhibition and disease. J Abnorm Psychol. 1986 Aug;95(3):274-81. — View Citation
Pisanti R, Lombardo C, Luszczynska A, Poli L, Bennardi L, Giordanengo L, Berloco PB, Violani C. Appraisal of transplant-related stressors, coping strategies, and psychosocial adjustment following kidney transplantation. Stress Health. 2017 Oct;33(4):437-447. doi: 10.1002/smi.2727. Epub 2016 Nov 9. — View Citation
Prihodova L, Nagyova I, Rosenberger J, Majernikova M, Roland R, Groothoff JW, van Dijk JP. Adherence in patients in the first year after kidney transplantation and its impact on graft loss and mortality: a cross-sectional and prospective study. J Adv Nurs. 2014 Dec;70(12):2871-83. doi: 10.1111/jan.12447. Epub 2014 May 22. — View Citation
Rebafka A. Medication Adherence After Renal Transplantation-a Review of the Literature. J Ren Care. 2016 Dec;42(4):239-256. doi: 10.1111/jorc.12181. Epub 2016 Sep 15. Review. — View Citation
Smyth JM, Stone AA, Hurewitz A, Kaell A. Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. JAMA. 1999 Apr 14;281(14):1304-9. — View Citation
Solano L, Pepe L, Donati V, Persichetti S, Laudani G, Colaci A. Differential health effects of written processing of the experience of a surgical operation in high- and low-risk conditions. J Clin Psychol. 2007 Apr;63(4):357-69. — View Citation
* Note: There are 19 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Renal Function | In order to test the transplanted organ function the creatinine, CDK-EPI and azotemia level were measured through blood analysis at T0,T1,T2. | 3 months | |
Primary | Alexithymia - difficulties in identifying, recognizing and describing emotions | In order to evaluate the level of alexithymia the TAS-20 was administered before the operation, the day of the discharge and 3 months after the transplant. It is a self-administered questionnaire, consisting of 20 items. The scale ranges between 20 to 100 and it allows to identify alexithymic (> 60), not alexithymic (< 51) and probably alexithymic patients (51-60).We expect that those patients undergoing expressive writing would have a lower score (<51) compared to control group patients. | 3 months | |
Primary | Adherence | In order to assess the level of adherence, each patient had to answer to the following question: "Have you ever forgotten to take the drugs prescribed by your treatment plan?" with dichotomous answer yes / no | 3 months | |
Primary | Healthcare spending | In order to test the healthcare spending to all participants were asked (through a specific questionnaire built ad hoc for the specific situation) the number of medical visits, the number of hospitalizations, the number of admissions to emergency room for acute episodes, the number of hospitalizations stay days in the last year, after the operation and 3 months later. The study hypothesized an lower number of medical visits, hospitalization's days and admissions to emergency room for those patients who performed the expressive writing task. | 3 months | |
Secondary | Depressive symptoms | In order to test any variation in depressive symptoms the BDI -II was administered at T0,T1, and T2. The Scores 0-13 indicate an absence of depressive content, the scores between 14-19 a mild depression, the scores 27-29 a moderate grade depression and the scores 30-63: a severe depression. We expected a lover level of depression in all sample, and in particular lower level (0-13) in those who performed the expressive writing task. | 3 months | |
Secondary | Anxiety | In order to test any variation in anxiety level all participants completed STAI Y1, Y2 at T0, T1,T2. The scores between 80-71 represent very high level of state and trait anxiety, 70-51 represent medium-high level, 50-31 represent medium-low level and 30-20 none or very low level. We expected lower level of anxiety in all sample, but in particular lower level in those who performed the expressive writing task. | 3 months | |
Secondary | Empathy | In order to test the level of empathy the IRI questionnaire was administered at T0,T1,T2. It is a multidimensional scale composed of 28 self-report items designed to measure both cognitive and emotional components of empathy. The subscale scores range from 0 to 28. We expected higher level of empathy in those who performed the expressive writing task. | 3 months | |
Secondary | Resilience | In order to test the level of resilience, the CD-RISC Connor Davidson Resilience Scale was administered at T0,T1,T2. It is a self- administered questionnaire composed of 25 item and 5 subscales, with higher scores reflecting greater resilience. The score range from 0 to 100. We expected higher level of resilience in those who performed the expressive writing task. | 3 months | |
Secondary | Health Locus of control (HLC) | In order to test the patient's beliefs about the state of health, the Health Locus of Control test was administered at T0,T1,T2. It is a self- administered questionnaire composed of 11 item and 2 subscales (external locus of control and internal locus of control). The score ranges from 0 to 55. We expected higher level of internal locus of control in those who performed the expressive writing task. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04491552 -
TruGraf® Long-term Clinical Outcomes Study
|
||
Withdrawn |
NCT04560582 -
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
|
||
Completed |
NCT05747274 -
SRDK0921_ Analytical Performance Study
|
||
Not yet recruiting |
NCT05482100 -
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
|
||
Recruiting |
NCT06243289 -
Improving KIdney Transplantation With Cellular Therapy Study
|
||
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
Enrolling by invitation |
NCT06126380 -
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
|
Phase 2 | |
Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
Active, not recruiting |
NCT03714113 -
Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT04091984 -
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
|
||
Recruiting |
NCT05335538 -
TruGraf and TRAC In Pediatrics Study
|
||
Completed |
NCT03663335 -
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
|
Phase 2 | |
Completed |
NCT03652402 -
Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
|
||
Recruiting |
NCT04773392 -
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
|
Phase 4 | |
Terminated |
NCT02974686 -
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
|
Phase 4 | |
Completed |
NCT03873623 -
The TOGETHER Project - Kidney
|
||
Terminated |
NCT04156204 -
Immunosuppressant Medication Dosed Daily After Kidney Transplant
|
Early Phase 1 | |
Completed |
NCT04601155 -
Transition of Renal Patients Using AlloSure Into Community Kidney Care
|
||
Completed |
NCT03874299 -
The TOGETHER Project - Kidney RNA-seq Validation
|